Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird Bio for about $29 million. Meanwhile, Pfizer continued the culling of its gene therapies with the discontinuation of Beqvez for hemophilia B.
The post Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees to Acquisition by Private Equity appeared first on MedCity News.
